Eqis Capital Management, Inc. Eli Lilly & CO Transaction History

Eqis Capital Management, Inc.

$1.21 Billion
Q3 2024

A detailed history of Eqis Capital Management, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 4,142 shares of LLY stock, worth $3.3 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares

4,142

Previous 3,828 8.2%

Holding current value

$3.3 Million

Previous $3.47 Million 5.89%

% of portfolio

0.3%

Previous 0.3%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$772.14 - $960.02 $242,451 - $301,446	314 Added 8.2%	4,142 $3.67 Million
Q2 2024 Aug 13, 2024	SELL	$724.87 - $909.04 $78,285 - $98,176	-108 Reduced 2.74%	3,828 $3.47 Million
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $80,539 - $107,750	-136 Reduced 3.34%	3,936 $3.06 Million
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $92,433 - $108,966	-176 Reduced 4.14%	4,072 $2.37 Million
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $363,843 - $501,614	837 Added 24.54%	4,248 $2.28 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $255,689 - $341,886	729 Added 27.18%	3,411 $1.6 Million
Q1 2023 May 15, 2023	SELL	$310.63 - $364.82 $252,852 - $296,963	-814 Reduced 23.28%	2,682 $921,000
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $20,579 - $23,978	64 Added 1.86%	3,496 $1.28 Million
Q3 2022 Oct 24, 2022	SELL	$296.48 - $337.87 $475,257 - $541,605	-1,603 Reduced 31.84%	3,432 $1.11 Million
Q2 2022 Aug 08, 2022	BUY	$278.73 - $327.27 $101,178 - $118,799	363 Added 7.77%	5,035 $1.63 Million
Q1 2022 May 16, 2022	SELL	$234.69 - $291.66 $253,934 - $315,576	-1,082 Reduced 18.8%	4,672 $1.34 Million
Q4 2021 Feb 14, 2022	BUY	$224.85 - $279.04 $593,154 - $736,107	2,638 Added 84.66%	5,754 $1.59 Million
Q3 2021 Nov 12, 2021	SELL	$221.6 - $272.71 $196,780 - $242,166	-888 Reduced 22.18%	3,116 $720,000
Q2 2021 Aug 12, 2021	SELL	$180.55 - $233.54 $264,505 - $342,136	-1,465 Reduced 26.79%	4,004 $919,000
Q1 2021 May 14, 2021	BUY	$164.32 - $212.72 $26,619 - $34,460	162 Added 3.05%	5,469 $1.02 Million
Q4 2020 Feb 11, 2021	SELL	$130.46 - $172.63 $187,601 - $248,241	-1,438 Reduced 21.32%	5,307 $896,000
Q3 2020 Nov 10, 2020	SELL	$146.22 - $169.13 $253,837 - $293,609	-1,736 Reduced 20.47%	6,745 $998,000
Q2 2020 Aug 10, 2020	SELL	$136.42 - $164.18 $27,011 - $32,507	-198 Reduced 2.28%	8,481 $1.39 Million
Q1 2020 May 12, 2020	SELL	$119.05 - $147.35 $66,548 - $82,368	-559 Reduced 6.05%	8,679 $1.27 Million
Q4 2019 Jan 24, 2020	SELL	$106.92 - $132.43 $109,058 - $135,078	-1,020 Reduced 9.94%	9,238 $1.21 Million
Q3 2019 Nov 05, 2019	SELL	$106.79 - $116.16 $26,163 - $28,459	-245 Reduced 2.33%	10,258 $1.15 Million
Q2 2019 Jul 18, 2019	SELL	$110.79 - $129.32 $314,975 - $367,656	-2,843 Reduced 21.3%	10,503 $1.16 Million
Q1 2019 Apr 18, 2019	BUY	$111.31 - $131.02 $446,464 - $525,521	4,011 Added 42.97%	13,346 $1.73 Million
Q4 2018 Jan 25, 2019	BUY	$105.9 - $118.64 $3,600 - $4,033	34 Added 0.37%	9,335 $1.08 Million
Q3 2018 Oct 17, 2018	BUY	$85.86 - $107.31 $61,990 - $77,477	722 Added 8.42%	9,301 $973,000
Q2 2018 Jul 27, 2018	BUY	$75.7 - $86.88 $222,785 - $255,687	2,943 Added 52.22%	8,579 $732,000
Q1 2018 Apr 06, 2018	SELL	$74.21 - $87.6 $338,471 - $399,543	-4,561 Reduced 44.73%	5,636 $436,000
Q4 2017 Jan 25, 2018	SELL	$81.94 - $87.89 $15,568 - $16,699	-190 Reduced 1.83%	10,197 $861,000
Q3 2017 Oct 03, 2017	BUY	$77.07 - $85.54 $800,526 - $888,503	10,387	10,387 $888,000

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.

Account

Eqis Capital Management, Inc. Eli Lilly & CO Transaction History